/PRNewswire/ Prelude Corporation (PreludeDxä), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that.
Recardio Inc., a clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the study results of Recardio's Phase 2 clinical study in Acute Myocardial Infarction will be presented on Saturday, May 21, 2022, during the Latebreaker Session at the World Congre.
No Effect of Omecamtiv Mecarbil On Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction Results Will Be Presented in Late Breaking Clinical Trial Session at the American. | February 15, 2022
Die Regionaldirektion der Bundesagentur für Arbeit legt am heutigen Donnerstag (10.00 Uhr) die September-Arbeitslosenzahlen für Bremen und Niedersachsen vor.